VHB Medi Sciences Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: VHB Medi Sciences Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $2.3M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

VHB Medi Sciences Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $2.3M Trade | TransData Nexus

VHB Medi Sciences Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $2.3M Total Trade · DGFT Verified

VHB Medi Sciences Limited is an Indian pharmaceutical exporter with a total trade value of $2.3M across 6 products in 4 therapeutic categories. Based on 75 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Vancomycin ($1.1M), Meropenem ($800.0K), Cisplatin ($174.3K).

VHB Medi Sciences Limited — Export Portfolio & Destination Treemap

VHB Medi Sciences Limited pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is VHB Medi Sciences Limited? — Company Overview & Market Position

VHB Medi Sciences Limited, established on September 12, 2007, is a public unlisted company headquartered in Mumbai, Maharashtra, India. The company is classified as a 'company limited by shares' under the Corporate Identification Number (CIN) U24232MH2007PLC174054. Its authorized capital stands at ₹25 crore, with a paid-up capital of ₹12.75 crore, reflecting a 51% paid-up ratio.

The company operates in the pharmaceutical manufacturing sector, focusing on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. VHB Medi Sciences Limited is part of the VHB Group, a conglomerate with a history dating back to 1946. The VHB Group has a significant presence in the pharmaceutical industry, with over 21 branch offices and 3,500 distribution centers, supported by a dedicated field force of over 2,500 professionals.

The company's registered office is located at 30 A, Government Industrial Estate, Charkop, Kandivali (West), Mumbai, Maharashtra 400067, India. As of the latest available data, VHB Medi Sciences Limited employs between 51 to 100 individuals.

What Does VHB Medi Sciences Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Vancomycin$1.1M

Product Portfolio — Top 6 by Export Value

VHB Medi Sciences Limited exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Vancomycin	Antibiotics	$1.1M	22	1.2%	11
2	Meropenem	Advanced Antibiotics	$800.0K	16	0.4%	7
3	Cisplatin	Oncology	$174.3K	16	1.4%	13
4	Dacarbazine	Advanced Oncology	$102.7K	12	7.2%	4
5	Cytarabine	Advanced Oncology	$59.7K	4	0.6%	14
6	Daunorubicin	Advanced Oncology	$17.5K	5	2.5%	7

VHB Medi Sciences Limited exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $2.3M. The top category is Antibiotics (48.8% of portfolio), followed by Advanced Antibiotics (35.5%), indicating a concentrated portfolio with the top 5 products accounting for 99.2% of total export value.

VHB Medi Sciences Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

VHB Medi Sciences Limited operates manufacturing facilities designed to meet international standards, including those set by the US FDA and UK MHRA. These facilities specialize in the production of parenteral formulations, particularly injectables, with an annual capacity of 180 million units. The company's manufacturing plants are strategically located to cater to both domestic and international markets, ensuring efficient production and distribution.

3Key Leadership

The leadership team at VHB Medi Sciences Limited comprises experienced professionals committed to the company's growth and innovation. The Managing Director, Ms. Anju Gupta Kaudanya, has been recognized for her contributions to the pharmaceutical industry, including receiving the 'Most Technically & Scientifically Advanced Pharmaceutical Manufacturing Unit of the Year' award in 2013. Other key executives include Mr. R.C. Bhagat, Chairman of VHB Life Sciences Ltd., who was honored with the 'Lifetime Achievement Award' in the same year. The Board of Directors includes individuals such as Ashokkumar Keshrimal Jain, Uttamchand Kesharimal Jain, Pravin Keshrimal Jain, Kishore Champalal Solanki, Rahul Ashokkumar Jain, Rahul Ashok Jain, Pradip Chotabhai Patel, and Brij Gopal Kankani.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does VHB Medi Sciences Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

VHB Medi Sciences Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are designed to comply with international standards, such as those set by the US FDA and UK MHRA, facilitating market access in these regions. While specific regulatory filings and approvals are not detailed in the available sources, the company's adherence to these standards indicates a commitment to meeting the stringent requirements of regulated markets.

2Emerging Markets

VHB Medi Sciences Limited has expanded its reach to emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on high-quality branded generic formulations has enabled it to cater to both regulated and emerging markets. Additionally, the company's manufacturing facilities are designed to meet international standards, such as those set by the US FDA and UK MHRA, which may facilitate access to markets requiring WHO prequalification. However, specific details regarding WHO prequalification are not available in the provided sources.

3Geographic Strategy

VHB Medi Sciences Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding VHB Medi Sciences Limited's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not available in the provided sources. However, the company's manufacturing facilities are designed to meet international standards, including those set by the US FDA, indicating a commitment to compliance with FDA regulations.

2WHO & EU GMP

VHB Medi Sciences Limited's manufacturing facilities are designed to meet international standards, including those set by the US FDA and UK MHRA. While specific certifications such as WHO prequalification and EU GMP certificates are not detailed in the available sources, the company's adherence to these standards suggests a commitment to quality and regulatory compliance.

3CDSCO & Indian Regulatory

VHB Medi Sciences Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, ensuring compliance with Indian regulatory requirements. The company's manufacturing facilities are designed to meet international standards, reflecting a commitment to quality and regulatory compliance.

VHB Medi Sciences Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

VHB Medi Sciences Limited operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific market share comparisons are not available in the provided sources, the company's focus on high-quality branded generic formulations and adherence to international manufacturing standards position it as a competitive entity in both regulated and emerging markets.

2Key Differentiators

VHB Medi Sciences Limited's key differentiators include its specialization in parenteral formulations, particularly injectables, with an annual production capacity of 180 million units. The company's manufacturing facilities are designed to meet international standards, including those set by the US FDA and UK MHRA, ensuring high-quality production. Additionally, VHB Medi Sciences Limited has a significant global presence, supplying high-quality branded generic formulations to over 54 countries, catering to both regulated and emerging markets.

3Strategic Position

VHB Medi Sciences Limited's current strategic direction focuses on the development and production of parenteral formulations, particularly injectables, with an annual capacity of 180 million units. The company's adherence to international manufacturing standards, such as those set by the US FDA and UK MHRA, positions it to serve both regulated and emerging markets effectively. Looking ahead, VHB Medi Sciences Limited aims to leverage its manufacturing capabilities and global presence to drive growth and innovation in the pharmaceutical sector.

Buyer Due Diligence Brief — Evaluating VHB Medi Sciences Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

VHB Medi Sciences Limited has demonstrated a consistent track record in the pharmaceutical manufacturing sector, with an annual production capacity of 180 million injectables. The company's manufacturing facilities are designed to meet international standards, including those set by the US FDA and UK MHRA, indicating a commitment to quality and regulatory compliance. While specific export volumes and consistency are not detailed in the available sources, the company's global presence in over 54 countries suggests reliability in its supply chain operations.

2Certifications to Verify

Importers should verify the following certifications when considering VHB Medi Sciences Limited as a supplier:

FDA Registration: Confirm the company's FDA facility registrations to ensure compliance with US regulations.

WHO-GMP Certification: Verify WHO Good Manufacturing Practice certification to assess adherence to international quality standards.

Frequently Asked Questions — VHB Medi Sciences Limited

How many pharmaceutical products does VHB Medi Sciences Limited export from India?

VHB Medi Sciences Limited exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Vancomycin ($1.1M), Meropenem ($800.0K), Cisplatin ($174.3K), Dacarbazine ($102.7K), Cytarabine ($59.7K). Total export value is $2.3M.

What is VHB Medi Sciences Limited's total pharmaceutical export value?

VHB Medi Sciences Limited's total pharmaceutical export value is $2.3M, based on 75 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does VHB Medi Sciences Limited cover?

VHB Medi Sciences Limited exports across 4 therapeutic categories. The largest are Antibiotics (48.8%, 1 products), Advanced Antibiotics (35.5%, 1 products), Advanced Oncology (8.0%, 3 products).

Get Full VHB Medi Sciences Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.